Training and Resources
LYNPARZA® (olaparib) in prostate cancer
A guide to LYNPARZA® (olaparib) for patients with prostate cancer
GB-47457 | Date of Preparation: August 2023
Prostate prescribing information (tablets) GB / NI
[External links]
Guide for LYNPARZA® (olaparib) BRCA testing in prostate cancer
GB-47458 | Date of Preparation: October 2023
Prostate prescribing information (tablets) GB / NI
[External links]
More information about LYNPARZA® (olaparib) in prostate cancer:
LYNPARZA is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.1
LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated.1
Reference
Supporting documentation
100 mg and 150 mg film coated tablets – Great Britain
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet
100 mg and 150 mg film coated tablets – Northern Ireland
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet
